SYMPTOM BURDEN AMONG OLDER ADULTS WITH NON-HODGKIN LYMPHOMA UNDERGOING CHEMOTHERAPY IN SOME HOSPITAL OF HANOI
Main Article Content
Abstract
Objectives: To describe the prevalence and severity of symptoms among older adults with non-Hodgkin lymphoma undergoing chemotherapy at oncology hospitals in Hanoi.
Methods: A cross-sectional study was conducted on 139 older patients diagnosed with non-Hodgkin lymphoma at oncology hospitals in Hanoi.
Results: The sample consisted of 77 males (55.4%) and 62 females (44.6%), with a mean age of 68.1 ± 5.3 years. The most commonly reported symptoms included hair loss (77.7%), numbness/tingling in hands or feet (67.6%), dry mouth (59.7%), difficulty sleeping (62.6%), lack of appetite (52.5%), change in the way food tastes (50.4%), lack of energy (44.4%), shortness of breath (42.4%), weight loss (43.9%), and worrying (41.7%). Hair loss was the most severe symptom (mode = 3), while symptoms like numbness in extremities, dry mouth, appetite loss, taste changes, insomnia, shortness of breath, fatigue, and anxiety (mode = 2). Less frequent symptoms such as diarrhea, nausea, and sweats were mild (mode = 1). Some symptoms as mouth sores, feeling sad, and headache had a mode of 2 but a median of 1, indicating skewed perception of severity.
Conclusions: Older adults with non-Hodgkin lymphoma undergoing chemotherapy commonly experience multiple symptoms, notably hair loss, numbness/tingling in hands or feet, dry mouth, and difficulty sleeping. In terms of severity, most symptoms were rated as mild to moderate by patients, with only hair loss identified as severe (mode = 3). These findings reflect the complexity and diversity of symptom experiences among older adults with non-Hodgkin lymphoma receiving chemotherapy. The results underscore the need for healthcare professionals-particularly physicians and oncology nurses-to develop tailored symptom management and patient education materials to improve care quality and treatment outcomes for this vulnerable population.
Article Details
Keywords
Non‑Hodgkin lymphoma, elderly, symptoms, MSAS.
References
[2] Chu Y, Liu Y, Fang X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol, 2023, 13: 1059914. doi: 10.3389/fonc.2023.1059914.
[3] Global cancer observatory - Vietnam. https://gco.iarc.who.int/media/globocan/factsheets/populations/704-viet-nam-fact-sheet.pdf. 4//11/2025.
[4] Al Qadire M, Al Khalaileh M. Prevalence of symptoms and quality of life among Jordanian cancer patients. Clin Nurs Res, 2016, 25 (2): 174-191. doi: 10.1177/1054773814564212.
[5] Schmittlutz K, Marks R. Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Ther Adv Hematol, 2021, 12: 2040620721996484. Ther Adv Hematol. 2021 Mar 3:12:2040620721996484. doi: 10.1177/2040620721996484.
[6] Chang V.T, Hwang S. Memorial Symptom Assessment Scale. Expert Review of Pharmacoeconomics & Outcomes Research, 2004, 4 (2): 171-8. doi: 10.1586/14737167.4.2.171
[7] Hoang T.X.H, Le Q.T.L et al. Identifying symptom cluster in cancer patients undergoing chemotherapy-in Vietnam: A cross-sectional study. PLOS One, 2024, 19 (9): e0307725. doi: 10.1371/journal.pone.0307725.
[8] Seretny M, Currie G.L et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain, 2014, 155: 2461-2470. http://dx.doi.org/10.1016/j.pain.2014.09.020.
[9] Seretny M, Currie G.L et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain, 2014, 155 (12): 2461-2470. doi: 10.1016/j.pain.2014.09.020.
[10] Abad V.C, Guilleminault C. Insomnia in elderly patients: Recommendations for pharmacological management. Drugs Aging, 2018, 35 (9): 791-817. doi: 10.1007/s40266-018-0569-8.
[11] Koh Y.W, Kang H.J et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: Correlation with tumor-associated macrophages. Oncologist, 2012, 17 (6): 871-880. doi: 10.1634/theoncologist.2012-0034.
[12] Quesada S, Guichard A, Fiteni F. Cancer-related alopecia: From etiologies to global management. Cancers (Basel), 2021, 13 (21): 5556. doi: 10.3390/cancers13215556.
[13] Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. Journal of Pain and Symptom Management, 2010, 39 (5): 847-858. doi: 10.1016/j.jpainsymman.2009.09.012.